Non-injection drug use and hepatitis C among drug treatment clients in west central Mexico

Octavio Campollo, Sonia Roman, Arturo Panduro, Gabriel Hernandez, Lino Diaz-Barriga, Mario C. Balanzario, James K Cunningham

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: Research on hepatitis C virus (HCV) prevalence among non-injecting drug treatment clients in the United States, Europe and Asia indicate substantial differences by place. To date, little or no research on HCV and non-injection drug use (NIDU) has been conducted in Mexico. Methods: We examined the prevalence of HCV, hepatitis B virus (HBV), and HIV among non-injecting drug users (NIDUs) in community-based drug treatment (N= 122) and NIDUs in a prison-based drug treatment program (N= 30), both located in west central Mexico. Results: Among the community clients, prevalence was 4.1% (95% confidence interval [CI]: 1.8-9.2) for HCV, 5.7% for HBV (95% CI: 2.8-11.4), and 1.6% for HIV (95% CI: 0.4-5.8). Among the in-prison clients, prevalence was 40.0% (95% CI: 24.6-57.7) for HCV, 20.0% for HBV (95% CI: 9.5-37.3), and 6.7% for HIV (95% CI: 1.9-21.3). None of the clients were aware of being infected. Conclusion: The HCV prevalence found for the NIDU community treatment clients ranks among the lower HCV estimates published for NIDUs in treatment to date. The prevalence found for the in-prison clients ranks among the higher, raising a concern of possible elevated HCV infection among NIDUs in the west central Mexico prison-one compounded by the finding that none of this study's clients knew they were HCV positive.

Original languageEnglish (US)
Pages (from-to)269-272
Number of pages4
JournalDrug and Alcohol Dependence
Volume123
Issue number1-3
DOIs
StatePublished - Jun 1 2012

Fingerprint

Drug therapy
Hepatitis C
Mexico
Viruses
Hepacivirus
Prisons
Pharmaceutical Preparations
Confidence Intervals
Drug Users
Hepatitis B virus
Therapeutics
HIV
Virus Diseases
Research

Keywords

  • Hepatitis b virus
  • Hepatitis c virus
  • Mexico
  • Non-injection drug use
  • Prison

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Toxicology
  • Pharmacology
  • Pharmacology (medical)

Cite this

Non-injection drug use and hepatitis C among drug treatment clients in west central Mexico. / Campollo, Octavio; Roman, Sonia; Panduro, Arturo; Hernandez, Gabriel; Diaz-Barriga, Lino; Balanzario, Mario C.; Cunningham, James K.

In: Drug and Alcohol Dependence, Vol. 123, No. 1-3, 01.06.2012, p. 269-272.

Research output: Contribution to journalArticle

Campollo, O, Roman, S, Panduro, A, Hernandez, G, Diaz-Barriga, L, Balanzario, MC & Cunningham, JK 2012, 'Non-injection drug use and hepatitis C among drug treatment clients in west central Mexico', Drug and Alcohol Dependence, vol. 123, no. 1-3, pp. 269-272. https://doi.org/10.1016/j.drugalcdep.2011.11.009
Campollo O, Roman S, Panduro A, Hernandez G, Diaz-Barriga L, Balanzario MC et al. Non-injection drug use and hepatitis C among drug treatment clients in west central Mexico. Drug and Alcohol Dependence. 2012 Jun 1;123(1-3):269-272. https://doi.org/10.1016/j.drugalcdep.2011.11.009
Campollo, Octavio ; Roman, Sonia ; Panduro, Arturo ; Hernandez, Gabriel ; Diaz-Barriga, Lino ; Balanzario, Mario C. ; Cunningham, James K. / Non-injection drug use and hepatitis C among drug treatment clients in west central Mexico. In: Drug and Alcohol Dependence. 2012 ; Vol. 123, No. 1-3. pp. 269-272.
@article{4be861dbd3c543ad919b6aebd4977da9,
title = "Non-injection drug use and hepatitis C among drug treatment clients in west central Mexico",
abstract = "Background: Research on hepatitis C virus (HCV) prevalence among non-injecting drug treatment clients in the United States, Europe and Asia indicate substantial differences by place. To date, little or no research on HCV and non-injection drug use (NIDU) has been conducted in Mexico. Methods: We examined the prevalence of HCV, hepatitis B virus (HBV), and HIV among non-injecting drug users (NIDUs) in community-based drug treatment (N= 122) and NIDUs in a prison-based drug treatment program (N= 30), both located in west central Mexico. Results: Among the community clients, prevalence was 4.1{\%} (95{\%} confidence interval [CI]: 1.8-9.2) for HCV, 5.7{\%} for HBV (95{\%} CI: 2.8-11.4), and 1.6{\%} for HIV (95{\%} CI: 0.4-5.8). Among the in-prison clients, prevalence was 40.0{\%} (95{\%} CI: 24.6-57.7) for HCV, 20.0{\%} for HBV (95{\%} CI: 9.5-37.3), and 6.7{\%} for HIV (95{\%} CI: 1.9-21.3). None of the clients were aware of being infected. Conclusion: The HCV prevalence found for the NIDU community treatment clients ranks among the lower HCV estimates published for NIDUs in treatment to date. The prevalence found for the in-prison clients ranks among the higher, raising a concern of possible elevated HCV infection among NIDUs in the west central Mexico prison-one compounded by the finding that none of this study's clients knew they were HCV positive.",
keywords = "Hepatitis b virus, Hepatitis c virus, Mexico, Non-injection drug use, Prison",
author = "Octavio Campollo and Sonia Roman and Arturo Panduro and Gabriel Hernandez and Lino Diaz-Barriga and Balanzario, {Mario C.} and Cunningham, {James K}",
year = "2012",
month = "6",
day = "1",
doi = "10.1016/j.drugalcdep.2011.11.009",
language = "English (US)",
volume = "123",
pages = "269--272",
journal = "Drug and Alcohol Dependence",
issn = "0376-8716",
publisher = "Elsevier Ireland Ltd",
number = "1-3",

}

TY - JOUR

T1 - Non-injection drug use and hepatitis C among drug treatment clients in west central Mexico

AU - Campollo, Octavio

AU - Roman, Sonia

AU - Panduro, Arturo

AU - Hernandez, Gabriel

AU - Diaz-Barriga, Lino

AU - Balanzario, Mario C.

AU - Cunningham, James K

PY - 2012/6/1

Y1 - 2012/6/1

N2 - Background: Research on hepatitis C virus (HCV) prevalence among non-injecting drug treatment clients in the United States, Europe and Asia indicate substantial differences by place. To date, little or no research on HCV and non-injection drug use (NIDU) has been conducted in Mexico. Methods: We examined the prevalence of HCV, hepatitis B virus (HBV), and HIV among non-injecting drug users (NIDUs) in community-based drug treatment (N= 122) and NIDUs in a prison-based drug treatment program (N= 30), both located in west central Mexico. Results: Among the community clients, prevalence was 4.1% (95% confidence interval [CI]: 1.8-9.2) for HCV, 5.7% for HBV (95% CI: 2.8-11.4), and 1.6% for HIV (95% CI: 0.4-5.8). Among the in-prison clients, prevalence was 40.0% (95% CI: 24.6-57.7) for HCV, 20.0% for HBV (95% CI: 9.5-37.3), and 6.7% for HIV (95% CI: 1.9-21.3). None of the clients were aware of being infected. Conclusion: The HCV prevalence found for the NIDU community treatment clients ranks among the lower HCV estimates published for NIDUs in treatment to date. The prevalence found for the in-prison clients ranks among the higher, raising a concern of possible elevated HCV infection among NIDUs in the west central Mexico prison-one compounded by the finding that none of this study's clients knew they were HCV positive.

AB - Background: Research on hepatitis C virus (HCV) prevalence among non-injecting drug treatment clients in the United States, Europe and Asia indicate substantial differences by place. To date, little or no research on HCV and non-injection drug use (NIDU) has been conducted in Mexico. Methods: We examined the prevalence of HCV, hepatitis B virus (HBV), and HIV among non-injecting drug users (NIDUs) in community-based drug treatment (N= 122) and NIDUs in a prison-based drug treatment program (N= 30), both located in west central Mexico. Results: Among the community clients, prevalence was 4.1% (95% confidence interval [CI]: 1.8-9.2) for HCV, 5.7% for HBV (95% CI: 2.8-11.4), and 1.6% for HIV (95% CI: 0.4-5.8). Among the in-prison clients, prevalence was 40.0% (95% CI: 24.6-57.7) for HCV, 20.0% for HBV (95% CI: 9.5-37.3), and 6.7% for HIV (95% CI: 1.9-21.3). None of the clients were aware of being infected. Conclusion: The HCV prevalence found for the NIDU community treatment clients ranks among the lower HCV estimates published for NIDUs in treatment to date. The prevalence found for the in-prison clients ranks among the higher, raising a concern of possible elevated HCV infection among NIDUs in the west central Mexico prison-one compounded by the finding that none of this study's clients knew they were HCV positive.

KW - Hepatitis b virus

KW - Hepatitis c virus

KW - Mexico

KW - Non-injection drug use

KW - Prison

UR - http://www.scopus.com/inward/record.url?scp=84861222719&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861222719&partnerID=8YFLogxK

U2 - 10.1016/j.drugalcdep.2011.11.009

DO - 10.1016/j.drugalcdep.2011.11.009

M3 - Article

C2 - 22138538

AN - SCOPUS:84861222719

VL - 123

SP - 269

EP - 272

JO - Drug and Alcohol Dependence

JF - Drug and Alcohol Dependence

SN - 0376-8716

IS - 1-3

ER -